Transformative Healthcare Collaboration Opportunities Emerge from COVID-19 Pandemic

By Stephen Bernstein, Gary Emmanuel, Jennifer S. Geetter, Lisa Schmitz Mazur, Vernessa T. Pollard, Michael Ryan, Joshua Spielman and Kristian Werling on February 17, 2021

Posted In Employee Benefits, Health and Welfare Plans, Privacy and Data Security

The seismic, virtually overnight transformation of healthcare delivery as a result of the pandemic has flung open doors to innovation, as a diverse cross-section of digital health and life sciences stakeholders mobilize crisis resources; adjust operations for enhanced screening, sanitization and social distancing measures; harness telehealth capabilities to deliver healthcare remotely; and identify opportunities for smarter, better healthcare going forward.

Writing for The US-Israel Legal Review, partners from McDermott’s Health practice highlight the challenges and opportunities that digital health and life sciences operators and investors should consider as the industry charts a course through the post-pandemic changed healthcare landscape.

Access the article.

Tags: artificial intelligence, BARDA, CARES Act, CMS, coronavirus, COVID-19, EBIDTA, FDA, healthcare regulators, Office of Civil Rights, prescription drug pricing, telehealth, USDA

Stephen Bernstein
Stephen W. Bernstein specializes in e-health, “big data”, data engineering, deployment of digital health tools and solutions and health-related matters affected by the internet and the Health Insurance Portability and Accountability Act (HIPAA), as well as private equity investments, mergers, acquisitions, affiliations and joint ventures involving technology, digital health companies, hospitals and physicians. Stephen co-leads the Firm’s Digital Health Practice, which brings together McDermott lawyers from within and outside the Health Industry Advisory Practice Group to develop thought leadership, share information and collaborate on best practices, and is co-chair of the Firm’s Life Sciences Practice. Stephen served as global head of the Firm’s Health Practice from 2009-2018. He is a current member of the Firm’s Management Committee and has served on the Firm’s Compensation, Executive and Finance Committees. Read Stephen Bernstein's full bio.

Gary Emmanuel
Gary Emmanuel focuses his practice on corporate securities matters. With over 15 years of experience, Gary represents both domestic and foreign companies that are navigating the process of capital raising, including initial public offerings, registered direct offerings, follow-on offerings, private placements, private investment in public equities (PIPEs) and bridge financings. Gary has worked extensively with biotechnology and other life science companies, both as company counsel and as underwriter's counsel. Read Gary Emmanuel's full bio.

Jennifer S. Geetter
Jennifer S. Geetter advises global life sciences, health care and informatics clients on legal issues attendant to biomedical innovation, research compliance, financial relationship management, digital health practices, and global privacy and data security laws. Jennifer represents a broad range of clients. Read Jennifer Geetter's full bio.

Lisa Schmitz Mazur
Lisa Schmitz Mazur advises health care providers and technology companies on a variety of legal, regulatory and compliance matters with a particular focus on digital health topics, including telehealth, telemedicine, mobile health and consumer wellness. Lisa advises a variety of health care providers and technology companies involved in “digital health,” including assisting clients in developing and implementing telemedicine programs by advising on issues related to professional licensure, scope of practice, informed consent, prescribing and reimbursement. Lisa helps clients identify and understand the relevant legal issues, and develop and implement practical, forward-thinking solutions and strategies that meet the complex and still-evolving digital health regulatory landscape. Read Lisa Schmitz Mazur's full bio.

Vernessa T. Pollard
Vernessa T. Pollard advises companies on regulatory, compliance, enforcement and policy matters involving pharmaceuticals, medical devices, health information technology (HIT) and digital health solutions, services and software. She advises companies and investors on regulatory and compliance issues arising from mergers, acquisitions and other transactions involving Food and Drug Administration (FDA)-regulated products. She also counsels manufacturers, distributors and retailers on regulatory and compliance issues related to food and cosmetic marketing and safety. Read Vernessa Pollard's full bio.

Michael Ryan
Michael W. Ryan advises manufacturers, health care providers, developers, and investors on the legal, regulatory, and reimbursement issues that arise during the development and commercialization of medical devices, drugs, biological products, and clinical laboratory testing services. Read Michael Ryan's full bio.

Joshua Spielman
Joshua (Jed) E. Spielman has a national practice focused on the business aspects of health care law with an emphasis on mergers and acquisitions, joint ventures and contractual arrangements. Jed serves principally as counsel to private equity funds, public and private corporations, hospitals, physician practices and strategic investors in connection with a wide range of transactional, corporate, regulatory and governance matters. Read Jed Spielman's full bio.

Kristian Werling
Kristian (Krist) Werling represents private equity and strategic investors in a wide variety of transactional matters in the healthcare and life sciences industry. In this capacity, he works with cross-disciplinary teams to conduct legal due diligence and execute acquisitions and divestitures, as well as provide ongoing legal services to portfolio companies. Krist is a co-head of the Firm’s Private Equity Practice Group. Read Kristian Werling's full bio.

Transformative Healthcare Collaboration Opportunities Emerge from COVID-19 Pandemic

Related Posts

BLOG EDITORS

STAY CONNECTED

TOPICS

ARCHIVES

RECENT POSTS